Friday, August 30, 2019

CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma

SHANGHAI, Aug. 30, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell...



from PR Newswire: https://ift.tt/30I7Hix
Posted by at
Labels:

2 comments:

  1. AkshayOctober 31, 2020 at 5:47 AM

    Great Information sharing.I am very happy to read this article .. thanks for giving us go through info.Fantastic nice. I appreciate this post.L’Occitane Black Friday 2020

    ReplyDelete
  2. MichaelseoSeptember 15, 2021 at 11:32 PM

    Your content is nothing short of brilliant in many ways. I think this is engaging and eye-opening material. Thank you so much for caring about your content and your readers. ez aircon

    ReplyDelete

Subscribe to: Post Comments (Atom)